{
  "timestamp": "2025-07-28T21:34:13.199Z",
  "totalAssets": 5,
  "successfulRuns": 0,
  "failedRuns": 5,
  "averageScore": null,
  "averageDataQuality": null,
  "totalCriticalIssues": 0,
  "recommendations": [],
  "assetDetails": [
    {
      "asset": {
        "id": 6,
        "target": "GLP-1 Receptor",
        "indication": "Type 2 Diabetes",
        "therapeuticArea": "Endocrinology",
        "geography": "US",
        "developmentPhase": "Phase 3",
        "description": "High-value diabetes market with established GLP-1 class"
      },
      "score": 0,
      "dataQuality": 0,
      "criticalIssues": [],
      "recommendation": "N/A",
      "responseTime": 0,
      "cost": 0
    },
    {
      "asset": {
        "id": 7,
        "target": "TGF-β",
        "indication": "Idiopathic Pulmonary Fibrosis",
        "therapeuticArea": "Respiratory",
        "geography": "EU",
        "developmentPhase": "Phase 2",
        "description": "Orphan disease with high unmet need and premium pricing"
      },
      "score": 0,
      "dataQuality": 0,
      "criticalIssues": [],
      "recommendation": "N/A",
      "responseTime": 0,
      "cost": 0
    },
    {
      "asset": {
        "id": 8,
        "target": "BCL11A",
        "indication": "Sickle Cell Disease",
        "therapeuticArea": "Hematology",
        "geography": "Africa",
        "developmentPhase": "Phase 1",
        "description": "Gene therapy in emerging market with complex access dynamics"
      },
      "score": 0,
      "dataQuality": 0,
      "criticalIssues": [],
      "recommendation": "N/A",
      "responseTime": 0,
      "cost": 0
    },
    {
      "asset": {
        "id": 9,
        "target": "IL-23",
        "indication": "Psoriasis",
        "therapeuticArea": "Autoimmune",
        "geography": "Canada",
        "developmentPhase": "Approved",
        "description": "Established market with multiple approved competitors"
      },
      "score": 0,
      "dataQuality": 0,
      "criticalIssues": [],
      "recommendation": "N/A",
      "responseTime": 0,
      "cost": 0
    },
    {
      "asset": {
        "id": 10,
        "target": "Integrin α4β7",
        "indication": "Crohn's Disease",
        "therapeuticArea": "Gastroenterology",
        "geography": "Australia",
        "developmentPhase": "Phase 2",
        "description": "Specialty GI market with complex reimbursement landscape"
      },
      "score": 0,
      "dataQuality": 0,
      "criticalIssues": [],
      "recommendation": "N/A",
      "responseTime": 0,
      "cost": 0
    }
  ],
  "systemPerformance": {
    "averageResponseTime": 0,
    "totalCost": 0,
    "averageValidationCycles": 0
  }
}